SRTS vs. CATX, NNOX, SNWV, NYXH, ZIMV, SMTI, TCMD, STIM, NVRO, and TLSI
Should you be buying Sensus Healthcare stock or one of its competitors? The main competitors of Sensus Healthcare include Perspective Therapeutics (CATX), Nano-X Imaging (NNOX), Sanuwave Health (SNWV), Nyxoah (NYXH), ZimVie (ZIMV), Sanara MedTech (SMTI), Tactile Systems Technology (TCMD), Neuronetics (STIM), Nevro (NVRO), and TriSalus Life Sciences (TLSI). These companies are all part of the "medical equipment" industry.
Sensus Healthcare vs. Its Competitors
Sensus Healthcare (NASDAQ:SRTS) and Perspective Therapeutics (NYSE:CATX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, profitability, earnings, dividends, media sentiment, valuation, risk and analyst recommendations.
Sensus Healthcare has higher revenue and earnings than Perspective Therapeutics.
In the previous week, Sensus Healthcare had 1 more articles in the media than Perspective Therapeutics. MarketBeat recorded 3 mentions for Sensus Healthcare and 2 mentions for Perspective Therapeutics. Perspective Therapeutics' average media sentiment score of 0.80 beat Sensus Healthcare's score of 0.72 indicating that Perspective Therapeutics is being referred to more favorably in the news media.
Sensus Healthcare has a net margin of 4.56% compared to Perspective Therapeutics' net margin of -4,096.66%. Sensus Healthcare's return on equity of 3.34% beat Perspective Therapeutics' return on equity.
25.3% of Sensus Healthcare shares are owned by institutional investors. Comparatively, 54.7% of Perspective Therapeutics shares are owned by institutional investors. 8.9% of Sensus Healthcare shares are owned by company insiders. Comparatively, 3.7% of Perspective Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Sensus Healthcare has a beta of 1.29, suggesting that its stock price is 29% more volatile than the S&P 500. Comparatively, Perspective Therapeutics has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.
Sensus Healthcare presently has a consensus target price of $11.67, indicating a potential upside of 151.44%. Perspective Therapeutics has a consensus target price of $12.56, indicating a potential upside of 282.79%. Given Perspective Therapeutics' higher possible upside, analysts plainly believe Perspective Therapeutics is more favorable than Sensus Healthcare.
Summary
Sensus Healthcare beats Perspective Therapeutics on 9 of the 14 factors compared between the two stocks.
Get Sensus Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for SRTS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SRTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sensus Healthcare Competitors List
Related Companies and Tools
This page (NASDAQ:SRTS) was last updated on 7/2/2025 by MarketBeat.com Staff
